| __timestamp | Biogen Inc. | Regeneron Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 2232342000 | 504755000 |
| Thursday, January 1, 2015 | 2113100000 | 838526000 |
| Friday, January 1, 2016 | 1947900000 | 1177697000 |
| Sunday, January 1, 2017 | 1935500000 | 1320433000 |
| Monday, January 1, 2018 | 2106300000 | 1556200000 |
| Tuesday, January 1, 2019 | 2374700000 | 1834800000 |
| Wednesday, January 1, 2020 | 2504500000 | 1346000000 |
| Friday, January 1, 2021 | 2674300000 | 1824900000 |
| Saturday, January 1, 2022 | 2403600000 | 2115900000 |
| Sunday, January 1, 2023 | 2549700000 | 2631300000 |
| Monday, January 1, 2024 | 2403700000 | 2954400000 |
Unleashing the power of data
In the competitive landscape of biotechnology, understanding the financial strategies of industry leaders is crucial. Over the past decade, Regeneron Pharmaceuticals, Inc. and Biogen Inc. have demonstrated distinct approaches to managing Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Biogen's SG&A costs have shown a steady increase, peaking in 2021 with a 20% rise from 2014. In contrast, Regeneron has exhibited a more dynamic growth, with a staggering 421% increase in SG&A expenses over the same period, culminating in 2023. This divergence highlights Regeneron's aggressive expansion strategy compared to Biogen's more conservative approach. As these companies continue to innovate, their financial strategies will play a pivotal role in shaping their future trajectories. Investors and industry analysts should keep a keen eye on these trends to gauge the evolving dynamics of the biotech sector.
Eli Lilly and Company vs Regeneron Pharmaceuticals, Inc.: SG&A Expense Trends
Breaking Down SG&A Expenses: Johnson & Johnson vs Biogen Inc.
Regeneron Pharmaceuticals, Inc. or Catalyst Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Who Optimizes SG&A Costs Better? Regeneron Pharmaceuticals, Inc. or Protagonist Therapeutics, Inc.
Comparing SG&A Expenses: Regeneron Pharmaceuticals, Inc. vs Mesoblast Limited Trends and Insights
Regeneron Pharmaceuticals, Inc. and Dynavax Technologies Corporation: SG&A Spending Patterns Compared
Alnylam Pharmaceuticals, Inc. or Biogen Inc.: Who Manages SG&A Costs Better?
Who Optimizes SG&A Costs Better? Biogen Inc. or Exelixis, Inc.
Comparing SG&A Expenses: Biogen Inc. vs Alpine Immune Sciences, Inc. Trends and Insights
Operational Costs Compared: SG&A Analysis of Biogen Inc. and Xenon Pharmaceuticals Inc.
Biogen Inc. vs Catalyst Pharmaceuticals, Inc.: SG&A Expense Trends
Selling, General, and Administrative Costs: Biogen Inc. vs Dynavax Technologies Corporation